Isoflavones and postmenopausal women: A critical review

Treatments in Endocrinology

Volumn 1, Issue 5, 2002, Pages 293-311

  Phipps, William R ^a   Duncan, Alison M ^b   Kurzer, Mindy S ^c  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF GUELPH   (Canada)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA HYDROXYESTRONE; AROMATASE; BIOCHANIN A; BISPHOSPHONIC ACID DERIVATIVE; DAIDZEIN; DAIDZIN; EQUOL; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTRONE DERIVATIVE; FORMONONETIN; GENISTEIN; GENISTIN; GLUCOSIDE; GLYCITEIN; IPRIFLAVONE; ISOFLAVONE; LIGNAN; LIPOPROTEIN; PHYTOESTROGEN; PROTEIN TYROSINE KINASE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOYBEAN PROTEIN; STERYL SULFATASE; SULFOTRANSFERASE; TAMOXIFEN; TESTOSTERONE 17BETA DEHYDROGENASE; UNINDEXED DRUG;

ABSORPTION; BONE DENSITY; BONE MINERAL; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIET; ENDOMETRIUM CANCER; FEMALE; GENITAL SYSTEM DISEASE; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; META ANALYSIS; METABOLISM; NONHUMAN; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW;

CARDIOVASCULAR DISEASES; FEMALE; HUMANS; ISOFLAVONES; NEOPLASMS; OSTEOPOROSIS; POSTMENOPAUSE; RISK FACTORS;

EID: 0042861765     PISSN: 11756349     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024677-200201050-00003     Document Type: Review

References (255)

1. Barnes S. Evolution of the health benefits of soy isoflavones. Proc Soc Exp Biol Med 1998; 217: 386-92
2. Setchell KD, Brown NM, Desai P, et al. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr 2001; 131: 1362S-75S
3. Kurzer MS, Xu X. Dietary phytoestrogens. Annu Rev Nutr 1997; 17: 353-81
4. Knight DC, Eden JA. A review of the clinical effects of phytoestrogens. Obstet Gynecol 1996; 87: 897-904
5. Clarkson TB, Anthony MS, Williams JK, et al. The potential of soybean phytoestrogens for postmenopausal hormone replacement therapy. Proc Soc Exp Biol Med 1998; 217: 365-8
6. Murkies AL, Wilcox G, Davis SR. Clinical review 92: phytoestrogens. J Clin Endocrinol Metab 1998; 83: 297-303
7. Tham DM, Gardner CD, Haskell WL. Clinical review 97: potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metab 1998; 83: 2223-35
8. Messina MJ. Legumes and soybeans: overview of their nutritional profiles and health effects. Am J Clin Nutr 1999; 70: 439S-50S
9. Lissin LW, Cooke JP. Phytoestrogens and cardiovascular health. J Am Coll Cardiol 2000; 35: 1403-10
10. North American Menopause Society. The role of isoflavones in menopausal health: consensus opinion of The North American Menopause Society. Menopause 2000; 7: 215-29
11. Glazier MG, Bowman MA. A review of the evidence for the use of phytoestrogens as a replacement for traditional estrogen replacement therapy. Arch Intern Med 2001; 161: 1161-72
12. Vitolins MZ, Anthony M, Burke GL. Soy protein isoflavones, lipids and arterial disease. Curr Opin Lipidol 2001; 12: 433-7
13. Messina MJ, Loprinzi CL. Soy for breast cancer survivors: a critical review of the literature. J Nutr 2001; 131: 3095S-108S
14. Sirtori CR. Risks and benefits of soy phytoestrogens in cardiovascular diseases, cancer, climacteric symptoms and osteoporosis. Drug Saf 2001; 24: 665-82
15. Clarkson TB. Soy, soy phytoestrogens and cardiovascular disease. J Nutr 2002; 132: 566S-9S
16. Ginsburg J, Prelevic GM. Lack of significant hormonal effects and controlled trials of phyto-oestrogens. Lancet 2000; 355: 163-4
17. Clarkson TB. Soy phytoestrogens: what will be their role in postmenopausal hormone replacement therapy? Menopause 2000; 7: 71-5
18. Anderson JJ. Soy phytoestrogens, lipid reductions, and atherosclerosis delay in ovariectomized primates. J Clin Endocrinol Metab 2001; 86: 39-40
19. Eden JA. Managing the menopause: phyto-oestrogens or hormone replacement therapy? Ann Med 2001; 33: 4-6
20. Lichtenstein AH. Got soy? Am J Clin Nutr 2001; 73: 667-8
21. Gallagher JC. Meeting the bean half way. Menopause 2001; 8: 152-3
22. Elkind-Hirsch K. Effect of dietary phytoestrogens on hot flushes: can soy-based proteins substitute for traditional estrogen replacement therapy? Menopause 2001; 8: 154-6
23. Lobo RA. Dietary soy and cardiovascular disease risk. Menopause 2001; 8: 303-4
24. Davis SR. Phytoestrogen therapy for menopausal symptoms? BMJ 2001; 323: 354-5
25. Naftolin F, Guadalupe Stanbury M. Phytoestrogens: are they really estrogen mimics? Fertil Steril 2002; 77: 15-7
26. Kimira M, Arai Y, Shimoi K, et al. Japanese intake of flavonoids and isoflavonoids from foods. J Epidemiol 1998; 8: 168-75
27. Chen Z, Zheng W, Custer LJ, et al. Usual dietary consumption of soy foods and its correlation with the excretion rate of isoflavonoids in overnight urine samples among Chinese women in Shanghai. Nutr Cancer 1999; 33: 82-7
28. Wakai K, Egami I, Kato K, et al. Dietary intake and sources of isoflavones among Japanese. Nutr Cancer 1999; 33: 139-45
29. Coward L, Barnes NC, Setchell KDR, et al. Genistein, daidzein, and their b-glycoside conjugates: antitumor isoflavones in soybean foods from American and Asian diets. J Agric Food Chem 1993; 41: 1961-7
30. de Kleijn MJ, van der Schouw YT, Wilson PW, et al. Intake of dietary phytoestrogens is low in postmenopausal women in the United States: the Framingham study. J Nutr 2001; 131: 1826-32
31. Golbitz P. Traditional soyfoods: processing and products. J Nutr 1995; 125: 570S-2S
32. Anderson RL, Wolf WJ. Compositional changes in trypsin inhibitors, phytic acid, saponins and isoflavones related to soybean processing. J Nutr 1995; 125: 581S-8S
33. Izumi T, Piskula MK, Osawa S, et al. Soy isoflavone aglycones are absorbed faster and in higher amounts than their glucosides in humans. J Nutr 2000; 130: 1695-9
34. Adlercreutz H, Fotsis T, Lampe J, et al. Quantitative determination of lignans and isoflavonoids in plasma of omnivorous and vegetarian women by isotope dilution gas chromatography-mass spectrometry. Scand J Clin Lab Invest 1993; 53 Suppl. 215: 5-18
35. Shelnutt SR, Cimino CO, Wiggins PA, et al. Urinary pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein. Cancer Epidemiol Biomarkers Prev 2000; 9: 413-9
36. Zhang Y, Song TT, Cunnick JE, et al. Daidzein and genistein glucuronides in vitro are weakly estrogenic and activate human natural killer cells at nutritionally relevant concentrations. J Nutr 1999; 129: 399-405
37. Adlercreutz H, Martin F. Biliary excretion and intestinal metabolism of progesterone and estrogens in man. J Steroid Biochem 1980; 13: 231-44
38. Adlercreutz H, Höckerstedt K, Bannwart C, et al. Effect of dietary components, including lignans and phytoestrogens, on enterohepatic circulation and liver metabolism of estrogens and on sex hormone binding globulin (SHBG). J Steroid Biochem 1987; 27: 1135-44
39. Busby MG, Jeffcoat AR, Bloedon LT, et al. Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men. Am J Clin Nutr 2002; 75: 126-36
40. Lu LJ, Anderson KE. Sex and long-term soy diets affect the metabolism and excretion of soy isoflavones in humans. Am J Clin Nutr 1998; 68: 1500S-4S
41. Xu X, Wang HJ, Murphy PA, et al. Neither background diet nor type of soy food affects short-term isoflavone bioavailability in women. J Nutr 2000; 130: 798-801
42. Axelson M, Sjovall J, Gustafsson BE, et al. Soya: a dietary source of the non-steroidal oestrogen equol in man and animals. J Endocrinol 1984; 102: 49-56
43. Lampe JW, Karr SC, Hutchins AM, et al. Urinary equol excretion with a soy challenge: influence of habitual diet. Proc Soc Exp Biol Med 1998; 217: 335-9
44. Rowland IR, Wiseman H, Sanders TA, et al. Interindividual variation in metabolism of soy isoflavones and lignans: influence of habitual diet on equol production by the gut microflora. Nutr Cancer 2000; 36: 27-32
45. Lampe JW, Skor HE, Li S, et al. Wheat bran and soy protein feeding do not alter urinary excretion of the isoflavan equol in premenopausal women. J Nutr 2001; 131: 740-4
46. Duncan AM, Merz-Demlow BE, Xu X, et al. Premenopausal equol excretors show plasma hormone profiles associated with lowered risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2000; 9: 581-6
47. Barnes S. Oestrogens and their promiscuous receptors: confronting reality. Biochem Soc Trans 2001; 29: 231-6
48. Gustafsson J-Å. Estrogen receptor b: a new dimension in estrogen mechanism of action. J Endocrinol 1999; 163: 379-83
49. Speroff L. A clinical understanding of the estrogen receptor. Ann N Y Acad Sci 2000; 900: 26-39
50. Kuiper GG, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor b. Endocrinology 1998; 139: 4252-63
51. Dornstauder E, Jisa E, Unterrieder I, et al. Estrogenic activity of two standardized red clover extracts (Menoflavon) intended for large scale use in hormone replacement therapy. J Steroid Biochem Mol Biol 2001; 78: 67-75
52. Morito K, Hirose T, Kinjo J, et al. Interaction of phytoestrogens with estrogen receptors alpha and beta. Biol Pharm Bull 2001; 24: 351-6
53. An J, Tzagarakis-Foster C, Scharschmidt TC, et al. Estrogen receptor beta-selective transcriptional activity and recruitment of coregulators by phytoestrogens. J Biol Chem 2001; 276: 17808-14
54. Adlercreutz H, Bannwart C, Wahala K, et al. Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens. J Steroid Biochem Mol Biol 1993; 44: 147-53
55. Kao YC, Zhou C, Sherman M, et al. Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: a site-directed mutagenesis study. Environ Health Perspect 1998; 106: 85-92
56. Krazeisen A, Breitling R, Moller G, et al. Phytoestrogens inhibit human 17b-hydroxysteroid dehydrogenase type 5. Mol Cell Endocrinol 2001; 171: 151-62
57. Kirk CJ, Harris RM, Wood DM, et al. Do dietary phytoestrogens influence susceptibility to hormone-dependent cancer by disrupting the metabolism of endogenous oestrogens? Biochem Soc Trans 2001; 29: 209-16
58. Duncan AM, Merz BE, Xu X, et al. Soy isoflavones exert modest hormonal effects in premenopausal women. J Clin Endocrinol Metab 1999; 84: 192-7
59. Martini MC, Dancisak BB, Haggans CJ, et al. Effects of soy intake on sex hormone metabolism in premenopausal women. Nutr Cancer 1999; 34: 133-9
60. Wu AH, Stanczyk FZ, Hendrich S, et al. Effects of soy foods on ovarian function in premenopausal women. Br J Cancer 2000; 82: 1879-86
61. Kumar NB, Cantor A, Allen K, et al. The specific role of isoflavones on estrogen metabolism in premenopausal women. Cancer 2002; 94: 1166-74
62. Maskarinec G, Williams AE, Inouye JS, et al. A randomized isoflavone intervention among premenopausal women. Cancer Epidemiol Biomarkers Prev 2002; 11: 195-201
63. Baird DD, Umbach DM, Lansdell L, et al. Dietary intervention study to assess estrogenicity of dietary soy among postmenopausal women. J Clin Endocrinol Metab 1995; 80: 1685-90
64. Duncan AM, Underhill KEW, Xu X, et al. Modest hormonal effects of soy isoflavones in postmenopausal women. J Clin Endocrinol Metab 1999; 84: 3479-84
65. Scambia G, Mango D, Signorile PG, et al. Clinical effects of a standardized soy extract in postmenopausal women: a pilot study. Menopause 2000; 7: 105-11
66. Upmalis DH, Lobo R, Bradley L, et al. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. Menopause 2000; 7: 236-42
67. Pino AM, Valladares LE, Palma MA, et al. Dietary isoflavones affect sex hormone-binding globulin levels in postmenopausal women. J Clin Endocrinol Metab 2000; 85: 2797-800
68. Han KK, Soares JM, Haidar MA, et al. Benefits of soy isoflavone therapeutic regimen on menopausal symptoms. Obstet Gynecol 2002; 99: 389-94
69. Persky VW, Turyk ME, Wang L, et al. Effect of soy protein on endogenous hormones in postmenopausal women. Am J Clin Nutr 2002; 75: 145-53
70. Liehr JG. Is estradiol a genotoxic mutagenic carcinogen? Endocr Rev 2000; 21: 40-54
71. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001; 344: 276-85
72. Swaneck GE, Fishman J. Covalent binding of the endogenous estrogen 16a-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. Proc Natl Acad Sci U S A 1988; 85: 7831-5
73. Telang NT, Suto A, Wong GY, et al. Induction by estrogen metabolite 16a-hydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. J Natl Cancer Inst 1992; 84: 634-8
74. Cavalieri EL, Stack DE, Devanesan PD, et al. Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci U S A 1997; 94: 10937-42
75. Schneider J, Kinne D, Fracchia A, et al. Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc Natl Acad Sci U S A 1982; 79: 3047-51
76. Fishman J, Schneider J, Hershcope RJ, et al. Increased estrogen-16a-hydroxylase activity in women with breast and endometrial cancer. J Steroid Biochem 1984; 20: 1077-81
77. Kabat GC, Chang CJ, Sparano JA, et al. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 1997; 6: 505-9
78. Meilahn EN, De Stavola B, Allen DS, et al. Do urinary oestrogen metabolites predict breast cancer?.: Guernsey III cohort follow-up. Br J Cancer 1998; 78: 1250-5
79. Muti P, Bradlow HL, Micheli A, et al. Estrogen metabolism and risk of breast cancer: a prospective study of the 2: 16a-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology 2000; 11: 635-40
80. Xu X, Duncan AM, Merz BE, et al. Effects of soy isoflavones on estrogen and phytoestrogen metabolism in premenopausal women. Cancer Epidemiol Biomarkers Prev 1998; 7: 1101-8
81. Lu LJ, Cree M, Josyula S, et al. Increased urinary excretion of 2-hydroxyestrone but not 16a-hydroxyestrone in premenopausal women during a soya diet containing isoflavones. Cancer Res 2000; 60: 1299-305
82. Xu X, Duncan AM, Wangen KE, et al. Soy consumption alters endogenous estrogen metabolism in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2000; 9: 781-6
83. Mendelsohn ME. Nongenomic, ER-mediated activation of endothelial nitric oxide synthase: how does it work? What does it mean? Circ Res 2000; 87: 956-60
84. Gruber CJ, Tschugguel W, Schneeberger C, et al. Production and actions of estrogens. N Engl J Med 2002; 346: 340-52
85. Jayachandran M, Miller VM. Molecular and cellular mechanisms of estrogen's actions. In: Douglas PS, editor. Cardiovascular disease and disease in women. 2nd ed. New York: WB Saunders Company, 2002: 207-30
86. Kim H, Peterson TG, Barnes S. Mechanisms of action of the soy isoflavone genistein: emerging role for its effects via transforming growth factor beta signaling pathways. Am J Clin Nutr 1998; 68: 1418S-25S
87. Birt DF, Hendrich S, Wang W. Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol Ther 2001; 90: 157-77
88. Bouker KB, Hilakivi-Clarke L. Genistein: does it prevent or promote breast cancer? Environ Health Perspect 2000; 108: 701-8
89. Nestel PJ, Yamashita T, Sasahara T, et al. Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women. Arterioscler Thrombo Vasc Biol 1997; 17: 3392-8
90. Nestel PJ, Pomeroy S, Kay S, et al. Isoflavones from red clover improve systemic arterial compliance but not plasma lipids in menopausal women. J Clin Endocrinol Metab 1999; 84: 895-8
91. Wangen KE, Duncan AM, Xu X, et al. Soy isoflavones improve plasma lipids in normocholesterolemic and mildly hypercholesterolemic postmenopausal women. Am J Clin Nutr 2001; 73: 225-31
92. Gardner CD, Newell KA, Cherin R, et al. The effect of soy protein with or without isoflavones relative to milk protein on plasma lipids in hypercholesterolemic postmenopausal women. Am J Clin Nutr 2001; 73: 728-35
93. American Society for Reproductive Medicine. Reassessing estrogen replacement in cardiovascular disease. ASRM Committee Opinion. Birmingham (AL): ASRM, 2001
94. Stuenkel CA, Barrett-Conner E. Lessons from human trials. In: Douglas PS, editor. Cardiovascular disease and disease in women. 2nd ed. New York: WB Saunders Company, 2002: 257-77
95. Whitten CG, Shultz TD. Binding of steroid hormones in vitro by water-insoluble dietary fiber. Nutr Res 1988; 8: 1223-35
96. Goldin BR, Adlercreutz H, Gorbach SL, et al. Estrogen excretion patterns and plasma levels in vegetarian and omnivorous women. N Engl J Med 1982; 307: 1542-7
97. Longcope C, Gorbach S, Goldin B, et al. The effect of a low fat diet on estrogen metabolism. J Clin Endocrinol Metab 1987; 64: 1246-50
98. Michnovicz JJ, Bradlow HL. Dietary and pharmacological control of estradiol metabolism in humans. Ann N Y Acad Sci 1990; 595: 291-9
99. Anderson KE, Kappas A, Conney AH, et al. The influence of dietary protein and carbohydrate on the principal oxidative biotransformations of estradiol in normal subjects. J Clin Endocrinol Metab 1984; 59: 103-7
100. Michnovicz JJ, Adlercreutz H, Bradlow HL. Changes in levels of urinary estrogen metabolites after oral indole-3-carbinol treatment in humans. J Natl Cancer Inst 1997; 89: 718-23
101. Michnovicz JJ. Increased estrogen 2-hydroxylation in obese women using oral indole-3-carbinol. Int J Obes Relat Metab Disord 1998; 22: 227-9
102. Reichman ME, Judd JT, Longcope C, et al. Effects of alcohol consumption on plasma and urinary hormone concentrations in premenopausal women. J Natl Cancer Inst 1993; 85: 722-7
103. Longnecker MP, Newcomb PA, Mittendorf R, et al. Risk of breast cancer in relation to lifetime alcohol consumption. J Natl Cancer Inst 1995; 87: 923-9
104. Smith-Warner SA, Spiegelman D, Yaun SS, et al. Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA 1998; 279: 535-40
105. Lee HP, Gourley L, Duffy SW, et al. Dietary effects on breast-cancer risk in Singapore. Lancet 1991; 337: 1197-200
106. Wu AH, Ziegler RG, Horn-Ross PL, et al. Tofu and risk of breast cancer in Asian-Americans. Cancer Epidemiol Biomarkers Prev 1996; 5: 901-6
107. Ingram D, Sanders K, Kolybaba M, et al. Case-control study of phyto-oestrogens and breast cancer. Lancet 1997; 350: 990-4
108. Zheng W, Dai Q, Custer LJ, et al. Urinary excretion of isoflavonoids and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 1999; 8: 35-40
109. Dai Q, Shu XO, Jin F, et al. Population-based case-control study of soyfood intake and breast cancer risk in Shanghai. Br J Cancer 2001; 85: 372-8
110. Shu XO, Jin F, Dai Q, et al. Soyfood intake during adolescence and subsequent risk of breast cancer among Chinese women. Cancer Epidemiol Biomarkers Prev 2001; 10: 483-8
111. Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 1995; 333: 276-82
112. Sirtori CR, Gianazza E, Manzoni C, et al. Role of isoflavones in the cholesterol reduction by soy proteins in the clinic. Am J Clin Nutr 1997; 65: 166-7
113. Carroll KK, Kurowska EM. Soy consumption and cholesterol reduction: review of animal and human studies. J Nutr 1995; 125: 594S-7S
114. Potter SM. Soy protein and cardiovascular disease: the impact of bioactive components in soy. Nutr Rev 1998; 56: 231-5
115. Potter SM. Overview of proposed mechanisms for the hypocholesterolemic effect of soy. J Nutr 1995; 125: 606S-11S
116. Erdman Jr JW. AHA science advisory: soy protein and cardiovascular disease: a statement for healthcare professionals from the Nutrition Committee of the AHA. Circulation 2000; 102: 2555-9
117. Wagner JD, Cefalu WT, Anthony MS, et al. Dietary soy protein and estrogen replacement therapy improve cardiovascular risk factors and decrease aortic cholesteryl ester content in ovariectomized cynomolgus monkeys. Metabolism 1997; 46: 698-705
118. Alexandersen P, Haarbo J, Breinholt V, et al. Dietary phytoestrogens and estrogen inhibit experimental atherosclerosis. Climacteric 2001; 4: 151-9
119. Williams JK, Anthony MS, Herrington DM. Interactive effects of soy protein and estradiol on coronary artery reactivity in atherosclerotic, ovariectomized monkeys. Menopause 2001; 8: 307-13
120. Nurmi T, Mazur W, Heinonen S, et al. Isoflavone content of the soy based supplements. J Pharm Biomed Anal 2002; 28: 1-11
121. USDA-Iowa State University Database on the Isoflavone Content of Foods [online]. Available from URL: http://www.nal.usda.gov/fnic/foodcomp/Data/isoflav/isoflav.html. [Accessed 2002 Jul 24]
122. Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med 1994; 330: 1062-71
123. Manson JE, Martin KA. Clinical practice: postmenopausal hormone-replacement therapy. N Engl J Med 2001; 345: 34-40
124. Kessel B. Alternatives to estrogen for menopausal women. Proc Soc Exp Biol Med 1998; 217: 38-44
125. American College of Obstetricians and Gynecologists. Use of botanicals for management of menopausal symptoms. ACOG Practice Bulletin 28. Washington, DC: ACOG, 2001
126. Nagata C, Takatsuka N, Kawakami N, et al. Soy product intake and hot flashes in Japanese women: results from a community-based prospective study. Am J Epidemiol 2001; 153: 790-3
127. Adlercreutz H, Hämäläinen E, Gorbach S, et al. Dietary phyto-oestrogens and the menopause in Japan [letter]. Lancet 1992; 339: 1233
128. Brzezinski A, Adlercreutz H, Shaoul R, et al. Short-term effects of phytoestrogen-rich diet on postmenopausal women. Menopause 1997; 4: 89-94
129. Albertazzi P, Pansini F, Bonaccorsi G, et al. The effect of dietary soy supplementation on hot flushes. Obstet Gynecol 1998; 91: 6-11
130. Knight DC, Howes JB, Eden JA. The effect of Promensil, an isoflavone extract, on menopausal symptoms. Climacteric 1999; 2: 79-84
131. Baber RJ, Templeman C, Morton T, et al. Randomized placebo-controlled trial of an isoflavone supplement and menopausal symptoms in women. Climacteric 1999; 2: 85-92
132. Quella SK, Loprinzi CL, Barton DL, et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Treatment Group Trial. J Clin Oncol 2000; 18: 1068-74
133. St Germain A, Peterson CT, Robinson JG, et al. Isoflavone-rich or isoflavone-poor soy protein does not reduce menopausal symptoms during 24 weeks of treatment. Menopause 2001; 8: 17-26
134. Van Patten CL, Olivotto IA, Chambers GK, et al. Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol 2002; 20: 1449-55
135. Haas S, Walsh B, Evans S, et al. The effect of transdermal estradiol on hormone and metabolic dynamics over a six-week period. Obstet Gynecol 1988; 71: 671-6
136. This P, Magdelenat H. Phytoestrogens and adjuvant endocrine treatment of breast cancer. J Clin Oncol 2000; 18: 2792-3
137. Rebar RW. Practical evaluation of hormonal status. In: Yen SSC, Jaffe RB, Barbieri RL, editors. Reproductive endocrinology: physiology, pathophysiology, and clinical management. 4th ed. Philadelphia: WB Saunders Company, 1999: 709-47
138. Wilcox G, Wahlqvist ML, Burger HG, et al. Oestrogenic effects of plant foods in postmenopausal women. BMJ 1990; 301: 905-6
139. Murkies AL, Lombard C, Strauss BJ, et al. Dietary flour supplementation decreases post-menopausal hot flushes: effect of soy and wheat. Maturitas 1995; 21: 189-95
140. Albertazzi P, Pansini F, Bottazzi M, et al. Dietary soy supplementation and phytoestrogen levels. Obstet Gynecol 1999; 94: 229-31
141. Cline JM, Paschold JC, Anthony MS, et al. Effects of hormonal therapies and dietary soy phytoestrogens on vaginal cytology in surgically postmenopausal macaques. Fertil Steril 1996; 65: 1031-5
142. Chen GD, Oliver RH, Leung BS, et al. Estrogen receptor a and b expression in the vaginal walls and uterosacral ligaments of premenopausal and postmenopausal women. Fertil Steril 1999; 71: 1099-102
143. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 1801-11
144. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-13
145. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343: 522-9
146. Viscoli CM, Brass LM, Kernan WN, et al. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001; 345: 1243-9
147. Writing Group for the Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Womens Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-3
148. Mosca L, Collins P, Herrington DM, et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 2001; 104: 499-503
149. Food and Drug Administration. Food labeling: health claims: soy protein and coronary heart disease. Fed Regist 1999; 64: 57700-33
150. Anthony MS, Clarkson TB, Williams JK. Effects of soy isoflavones on atherosclerosis: potential mechanisms. Am J Clin Nutr 1998; 68: 1390S-3S
151. Baum JA, Teng H, Erdman Jr JW, et al. Long-term intake of soy protein improves blood lipid profiles and increases mononuclear cell low-density-lipoprotein receptor messenger RNA in hypercholesterolemic, postmenopausal women. Am J Clin Nutr 1998; 68: 545-51
152. Wong WW, Smith EO, Stuff JE, et al. Cholesterol-lowering effect of soy protein in normocholesterolemic and hypercholesterolemic men. Am J Clin Nutr 1998; 68: 1385S-9S
153. Washburn S, Burke GL, Morgan T, et al. Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women. Menopause 1999; 6: 7-13
154. Howes JB, Sullivan D, Lai N, et al. The effects of dietary supplementation with isoflavones from red clover on the lipoprotein profiles of post menopausal women with mild to moderate hypercholesterolaemia. Atherosclerosis 2000; 152: 143-7
155. Simons LA, von Konigsmark M, Simons J, et al. Phytoestrogens do not influence lipoprotein levels or endothelial function in healthy, postmenopausal women. Am J Cardiol 2000; 85: 1297-301
156. Hsu CS, Shen WW, Hsueh YM, et al. Soy isoflavone supplementation in postmenopausal women: effects on plasma lipids, antioxidant enzyme activities and bone density. J Reprod Med 2001; 46: 221-6
157. Dewell A, Hollenbeck CB, Bruce B. The effects of soy-derived phytoestrogens on serum lipids and lipoproteins in moderately hypercholesterolemic postmenopausal women. J Clin Endocrinol Metab 2002; 87: 118-21
158. Hodgson JM, Puddey IB, Beilin LJ, et al. Supplementation with isoflavonoid phytoestrogens does not alter serum lipid concentrations: a randomized controlled trial in humans. J Nutr 1998; 128: 728-32
159. Uesugi T, Fukui Y, Yamori Y. Beneficial effects of soybean isoflavone supplementation on bone metabolism and serum lipids in postmenopausal Japanese women: a four-week study. J Am Coll Nutr 2002; 21: 97-102
160. Clarkson TB, Anthony MS, Morgan TM. Inhibition of postmenopausal atherosclerosis progression: a comparison of the effects of conjugated equine estrogens and soy phytoestrogens. J Clin Endocrinol Metab 2001; 86: 41-7
161. Clarkson TB, Kaplan JR, Wagner JD, et al. Lessons from animal models. In: Douglas PS, editor. Cardiovascular disease and disease in women. 2nd ed. New York: WB Saunders Company, 2002: 231-256
162. Greaves KA, Parks JS, Williams JK, et al. Intact dietary soy protein, but not adding an isoflavone-rich soy extract to casein, improves plasma lipids in ovariectomized cynomolgus monkeys. J Nutr 1999; 129: 1585-92
163. Greaves KA, Wilson MD, Rudel LL, et al. Consumption of soy protein reduces cholesterol absorption compared to casein protein alone or supplemented with an isoflavone extract or conjugated equine estrogen in ovariectomized cynomolgus monkeys. J Nutr 2000; 130: 820-6
164. Crouse III JR, Morgan T, Terry JG, et al. A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins. Arch Intern Med 1999; 159: 2070-6
165. Merz-Demlow BE, Duncan AM, Wangen KE, et al. Soy isoflavones improve plasma lipids in normocholesterolemic, premenopausal women. Am J Clin Nutr 2000; 71: 1462-9
166. Anthony MS, Blair RM, Clarkson TB. Neither isoflavones nor the alcohol-extracted fraction added to alcohol-washed soy protein isolate restores the lipoprotein effects of soy protein isolate [abstract]. J Nutr 2002; 132: 583S
167. Messina M, Gardner C, Barnes S. Gaining insight into the health effects of soy but a long way still to go: commentary on the fourth International Symposium on the Role of Soy in Preventing and Treating Chronic Disease. J Nutr 2002; 132: 547S-51S
168. Dent SB, Peterson CT, Brace LD, et al. Soy protein intake by perimenopausal women does not affect circulating lipids and lipoproteins or coagulation and fibrinolytic factors. J Nutr 2001; 131: 2280-7
169. Teede HJ, Dalais FS, Kotsopoulos D, et al. Dietary soy has both beneficial and potentially adverse cardiovascular effects: a placebo-controlled study in men and postmenopausal women. J Clin Endocrinol Metab 2001; 86: 3053-60
170. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273: 199-208
171. Nilausen K, Meinertz H. Lipoprotein(a) and dietary proteins: casein lowers lipoprotein(a) concentrations as compared with soy protein. Am J Clin Nutr 1999; 69: 419-25
172. Kapiotis S, Hermann M, Held I, et al. Genistein, the dietary-derived angiogenesis inhibitor, prevents LDL oxidation and protects endothelial cells from damage by atherogenic LDL. Arterioscler Thromb Vasc Biol 1997; 17: 2868-74
173. Meng QH, Lewis P, Wahala K, et al. Incorporation of esterified soybean isoflavones with antioxidant activity into low density lipoprotein. Biochim Biophys Acta 1999; 1438: 369-76
174. Hwang J, Sevanian A, Hodis HN, et al. Synergistic inhibition of LDL oxidation by phytoestrogens and ascorbic acid. Free Radic Biol Med 2000; 29: 79-89
175. Kanazawa T, Osanai T, Zhang XS, et al. Protective effects of soy protein on the peroxidizability of lipoproteins in cerebrovascular diseases. J Nutr 1995; 125: 639S-46S
176. Tikkanen MJ, Wahala K, Ojala S, et al. Effect of soybean phytoestrogen intake on low density lipoprotein oxidation resistance. Proc Natl Acad Sci U S A 1998; 95: 3106-10
177. Wiseman H, O'Reilly JD, Adlercreutz H, et al. Isoflavone phytoestrogens consumed in soy decrease F(2)-isoprostane concentrations and increase resistance of low-density lipoprotein to oxidation in humans. Am J Clin Nutr 2000; 72: 395-400
178. Jenkins DJ, Kendall CW, Garsetti M, et al. Effect of soy protein foods on low-density lipoprotein oxidation and ex vivo sex hormone receptor activity: a controlled crossover trial. Metabolism 2000; 49: 537-43
179. Jenkins DJ, Kendall CW, Vidgen E, et al. Effect of soy-based breakfast cereal on blood lipids and oxidized low-density lipoprotein. Metabolism 2000; 49: 1496-500
180. Hodgson JM, Puddey IB, Croft KD, et al. Isoflavonoids do not inhibit in vivo lipid peroxidation in subjects with high-normal blood pressure. Atherosclerosis 1999; 145: 167-72
181. Samman S, Lyons Wall PM, Chan GS, et al. The effect of supplementation with isoflavones on plasma lipids and oxidisability of low density lipoprotein in premenopausal women. Atherosclerosis 1999; 147: 277-83
182. Hodgson JM, Puddey IB, Beilin LJ, et al. Effects of isoflavonoids on blood pressure in subjects with high-normal ambulatory blood pressure levels: a randomized controlled trial. Am J Hypertens 1999; 12: 47-53
183. Honoré EK, Williams JK, Anthony MS, et al. Soy isoflavones enhance coronary vascular reactivity in atherosclerotic female macaques. Fertil Steril 1997; 67: 148-54
184. Koh KK, Mincemoyer R, Bui MN, et al. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997; 336: 683-90
185. Gooderham MH, Adlercreutz H, Ojala ST, et al. A soy protein isolate rich in genistein and daidzein and its effects on plasma isoflavone concentrations, platelet aggregation, blood lipids and fatty acid composition of plasma phospholipid in normal men. J Nutr 1996; 126: 2000-6
186. Raines EW, Ross R. Biology of atherosclerotic plaque formation: possible role of growth factors in lesion development and the potential impact of soy. J Nutr 1995; 125: 624S-30S
187. Figtree GA, Griffiths H, Lu YQ, et al. Plant-derived estrogens relax coronary arteries in vitro by a calcium antagonistic mechanism. J Am Coll Cardiol 2000; 35: 1977-85
188. Marsh JD. Phytoestrogens and vascular therapy. J Am Coll Cardiol 2000; 35: 1986-7
189. Walker HA, Dean TS, Sanders TA, et al. The phytoestrogen genistein produces acute nitric oxide-dependent dilation of human forearm vasculature with similar potency to 17b-estradiol. Circulation 2001; 103: 258-62
190. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling: emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995; 332: 305-11
191. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. Belle Mead (NJ): Excerpta Medica Inc, 1998
192. American Society for Reproductive Medicine. Prevention and management of osteoporosis in women. ASRM Committee Opinion. Birmingham (AL): ASRM, 2001
193. Delmas PD, Bjarnasoa NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641-7
194. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282: 637-45
195. Modelska K, Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab 2002; 87: 16-23
196. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437-43
197. Hosking D, Chilvers CE, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med 1998; 338: 485-92
198. Bone HG, Greenspan SL, McKeever C, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab 2000; 85: 720-6
199. Tonino RP, Meunier PJ, Emkey R, et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 2000; 85: 3109-15
200. Mortensen L, Charles P, Bekker PJ, et al. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 1998; 83: 396-402
201. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282: 1344-52
202. Arjmandi BH, Birnbaum R, Goyal NV, et al. Bone-sparing effect of soy protein in ovarian hormone-deficient rats is related to its isoflavone content. Am J Clin Nutr 1998; 68: 1364S-8S
203. Arjmandi BH, Getlinger MJ, Goyal NV, et al. Role of soy protein with normal or reduced isoflavone content in reversing bone loss induced by ovarian hormone deficiency in rats. Am J Clin Nutr 1998; 68: 1358S-63S
204. Picherit C, Chanteranne B, Bennetau-Pelissero C, et al. Dose-dependent bones-paring effects of dietary isoflavones in the ovariectomised rat. Br J Nutr 2001; 85: 307-16
205. Lees CJ, Ginn TA. Soy protein isolate diet does not prevent increased cortical bone turnover in ovariectomized macaques. Calcif Tissue Int 1998; 62: 557-8
206. Alexandersen P, Toussaint A, Christiansen C, et al. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. JAMA 2001; 285: 1482-8
207. Lauderdale DS, Jacobsen SJ, Furner SE, et al. Hip fracture incidence among elderly Asian-American populations. Am J Epidemiol 1997; 146: 502-9
208. Somekawa Y, Chiguchi M, Ishibashi T, et al. Soy intake related to menopausal symptoms, serum lipids, and bone mineral density in postmenopausal Japanese women. Obstet Gynecol 2001; 97: 109-15
209. Ho SC, Chan SG, Yi Q, et al. Soy intake and the maintenance of peak bone mass in Hong Kong Chinese women. J Bone Miner Res 2001; 16: 1363-9
210. Mei J, Yeung SS, Kung AW. High dietary phytoestrogen intake is associated with higher bone mineral density in postmenopausal but not premenopausal women. J Clin Endocrinol Metab 2001; 86: 5217-21
211. Greendale GA, FitzGerald G, Huang MH, et al. Dietary soy isoflavones and bone mineral density: results from the study of women's health across the nation. Am J Epidemiol 2002; 155: 746-54
212. Kardinaal AF, Morton MS, Bruggemann-Rotgans IE, et al. Phyto-oestrogen excretion and rate of bone loss in postmenopausal women. Eur J Clin Nutr 1998; 52: 850-5
213. Clifton-Bligh PB, Baber RJ, Fulcher GR, et al. The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism. Menopause 2001; 8: 259-65
214. Scheiber MD, Liu JH, Subbiah MT, et al. NAMS fellowship findings: dietary inclusion of whole soy foods results in significant reductions in clinical risk factors for osteoporosis and cardiovascular disease in normal postmenopausal women. Menopause 2001; 8: 384-92
215. Potter SM, Baum JA, Teng H, et al. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr 1998; 68: 1375S-9S
216. Alekel DL, Germain AS, Peterson CT, et al. Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. Am J Clin Nutr 2000; 72: 844-52
217. Wangen KE, Duncan AM, Merz-Demlow BE, et al. Effects of soy isoflavones on markers of bone turnover in premenopausal and postmenopausal women. J Clin Endocrinol Metab 2000; 85: 3043-8
218. Kaufert P, Boggs PP, Ettinger B, et al. Women and menopause: beliefs, attitudes, and behaviors. The North American Menopause Society 1997 Menopause Survey. Menopause 1998; 5: 197-202
219. Kam IW, Dennehy CE, Tsourounis C. Dietary supplement use among menopausal women attending a San Francisco health conference. Menopause 2002; 9: 72-8
220. de Lemos ML. Effects of soy phytoestrogens genistein and daidzein on breast cancer growth. Ann Pharmacother 2001; 35: 1118-21
221. This P, De La Rochefordiere A, Clough K, et al. Phytoestrogens after breast cancer. Endocr Relat Cancer 2001; 8: 129-34
222. Bush TL, Whiteman M, Flaws JA. Hormone replacement therapy and breast cancer: a qualitative review. Obstet Gynecol 2001; 98: 498-508
223. Key TJ, Sharp GB, Appleby PN, et al. Soya foods and breast cancer risk: a prospective study in Hiroshima and Nagasaki, Japan. Br J Cancer 1999; 81: 1248-56
224. Zumoff B. Hormonal profiles in women with breast cancer. Obstet Gynecol Clin North Am 1994; 21: 751-72
225. Pike MC, Spicer DV, Dahmoush L, et al. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993; 15: 17-35
226. Spicer DV, Krecker EA, Pike MC. The endocrine prevention of breast cancer. Cancer Invest 1995; 13: 495-504
227. Kelsey JL, Horn-Ross PL. Breast cancer: magnitude of the problem and descriptive epidemiology. Epidemiol Rev 1993; 15: 7-16
228. McMichael-Phillips DF, Harding C, Morton M, et al. Effects of soy-protein supplementation on epithelial proliferation in the histologically normal human breast. Am J Clin Nutr 1998; 68: 1431S-5S
229. Hargreaves DF, Potten CS, Harding C, et al. Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J Clin Endocrinol Metab 1999; 84: 4017-24
230. Endl E, Gerdes J. The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res 2000; 257: 231-7
231. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000; 182: 311-22
232. Foth D, Cline JM. Effects of mammalian and plant estrogens on mammary glands and uteri of macaques. Am J Clin Nutr 1998; 68: 1413S-7S
233. Cline JM, Soderqvist G, Register TC, et al. Assessment of hormonally active agents in the reproductive tract of female nonhuman primates. Toxicol Pathol 2001; 29: 84-90
234. Ju YH, Doerge DR, Allred KF, et al. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic nude mice. Cancer Res 2002; 62: 2474-7
235. Ju YH, Allred CD, Allred KF, et al. Physiological concentrations of dietary genistein dose-dependently stimulate growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in athymic nude mice. J Nutr 2001; 131: 2957-62
236. Rose PG. Medical progress: endometrial carcinoma. N Engl J Med 1996; 335: 640-9
237. Southcott BM. Carcinoma of the endometrium. Drugs 2001; 61: 1395-405
238. Antunes CM, Strolley PD, Rosenshein NB, et al. Endometrial cancer and estrogen use: report of a large case-control study. N Engl J Med 1979; 300: 9-13
239. Shapiro S, Kelly JP, Rosenberg L, et al. Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. N Engl J Med 1985; 313: 969-72
240. Hale GE, Hughes CL, Cline JM. Endometrial cancer: hormonal factors, the perimenopausal 'window of risk', and isoflavones. J Clin Endocrinol Metab 2002; 87: 3-15
241. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339: 1609-18
242. Johnson EB, Muto MG, Yanushpolsky EH, et al. Phytoestrogen supplementation and endometrial cancer. Obstet Gynecol 2001; 98: 947-50
243. Goodman MT, Wilkens LR, Hankin JH, et al. Association of soy and fiber consumption with the risk of endometrial cancer. Am J Epidemiol 1997; 146: 294-306
244. Levine D, Gosink BB, Johnson LA. Change in endometrial thickness in postmenopausal women undergoing hormone replacement therapy. Radiology 1995; 197: 603-8
245. Exacoustos C, Lello S, Caporale E, et al. Monitoring of hormone replacement therapy in postmenopausal women by transvaginal sonography and color flow doppler: study in different phases of sequential therapy. Fertil Steril 1999; 71: 536-43
246. Hale GE, Hughes CL, Robboy SJ, et al. A double-blind randomized study on the effects of red clover isoflavones on the endometrium. Menopause 2001; 8: 338-46
247. Strom BL, Schinnar R, Ziegler EE, et al. Exposure to soy-based formula in infancy and endocrinological and reproductive outcomes in young adulthood. JAMA 2001; 286: 807-14
248. Lerner AJ. Women and Alzheimer's disease. J Clin Endocrinol Metab 1999; 84: 1830-4
249. Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology 2000; 54: 295-301
250. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA 2000; 283: 1007-15
251. Yaffe K, Krueger K, Sarkar S, et al. Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med 2001; 344: 1207-13
252. Mayeux R. Can estrogen or selective estrogen-receptor modulators preserve cognitive function in elderly women? N Engl J Med 2001; 344: 1242-4
253. Pan Y, Anthony M, Clarkson TB. Effect of estradiol and soy phytoestrogens on choline acetyltransferase and nerve growth factor mRNAs in the frontal cortex and hippocampus of female rats. Proc Soc Exp Biol Med 1999; 221: 118-25
254. White LR, Petrovitch H, Ross GW, et al. Brain aging and midlife tofu consumption. J Am Coll Nutr 2000; 19: 242-55
255. File SE, Jarrett N, Fluck E, et al. Eating soya improves human memory. Psychopharmacology (Berl) 2001; 157: 430-6